

## Drug Monograph

Drug/Drug     **Avar LS™ (sulfacetamide sodium and sulfur) Foam /**  
 Class:         **Topical Anti-Acne Agents**  
 Prepared for: MO HealthNet  
 Prepared by: Xerox Heritage, LLC

**New Criteria**

**Revision of Existing Criteria**

### Executive Summary

<b>Purpose:</b>	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.	
<b>Dosage Forms:</b>	Avar LS™ is available as aerosol foam. Each gram contains 100 mg (10%) of sodium sulfacetamide and 20 mg of colloidal sulfur (2%).	
<b>Manufacturer:</b>	Mission Pharmacal Company, San Antonio, TX 78230	
<b>Indications:</b>	Avar LS™ foam is indicated for use in the topical control of acne vulgaris, acne rosacea, and seborrheic dermatitis.	
<b>Costs:</b>	\$485 per 100 g container of Avar LS™. Wholesale Acquisition Cost	
<b>Summary of Findings:</b>	The MO HealthNet Division recommends prior authorization status for this product.	
<b>Status Recommendation:</b>	<input checked="" type="checkbox"/> Prior Authorization (PA) Required	<input type="checkbox"/> Open Access
	<input type="checkbox"/> Fiscal Edit	<input type="checkbox"/> PDL
<b>Type of PA Criteria:</b>	<input type="checkbox"/> Increased Risk of ADE	<input type="checkbox"/> Non-Preferred Agent
	<input checked="" type="checkbox"/> Appropriate Indications	<input type="checkbox"/> No PA Required

Prepared By: Luke Boehmer Pharm.D.  
 Date: November 10, 2015